Drug research

Nab-paclitaxel

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Abraxane

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )NCT07621718	RVMD	Phase 3	Recruiting	2028-12-30Estimated
A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183	AGEN	Phase 2	Completed	2026-01-05Actual
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT04329949	Corcept Therapeutics	Phase 3	Terminated	2021-08-23Actual
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317	Corcept Therapeutics	Phase 2	Recruiting	2027-09Estimated
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399	IBRX	Phase 2	Active not recruiting	2025-10-13Actual
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNCT06608927	RCUS	Phase 3	Active not recruiting	2030-11-30Estimated
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812	Corcept Therapeutics	Phase 2	Completed	2021-03-16Actual

RVMDRecruitingPrimary completion: 2028-12-30 · Estimated

Trial details

AGENCompletedPrimary completion: 2026-01-05 · Actual

Trial details

Corcept TherapeuticsTerminatedPrimary completion: 2021-08-23 · Actual

Trial details

Corcept TherapeuticsRecruitingPrimary completion: 2027-09 · Estimated

Trial details

IBRXActive not recruitingPrimary completion: 2025-10-13 · Actual

Trial details

RCUSActive not recruitingPrimary completion: 2030-11-30 · Estimated

Trial details

Corcept TherapeuticsCompletedPrimary completion: 2021-03-16 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.